In vitro cytokine licensing induces persistent permissive chromatin at the Indoleamine 2,3-dioxygenase promoter

Cytotherapy

Volumn 18, Issue 9, 2016, Pages 1114-1128

  Rovira Gonzalez, Yazmin I ^a   Lynch, Patrick J ^a   Thompson, Elaine E ^a   Stultz, Brian G ^a   Hursh, Deborah A ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

chromatin remodeling; cytokine licensing; histone modifications; immunomodulation; indoleamine 2,3 dioxygenase; mesenchymal stromal cells

Indexed keywords

GAMMA INTERFERON; HISTONE H3; INDOLEAMINE 2,3 DIOXYGENASE; MESSENGER RNA; TUMOR NECROSIS FACTOR; CYTOKINE; INDOLEAMINE 2,3-DIOXYGENASE 1, HUMAN;

ARTICLE; CHROMATIN; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; CRYOPRESERVATION; GENE EXPRESSION; GENE INDUCTION; HISTONE ACETYLATION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VITRO STUDY; MESENCHYMAL STROMA CELL; PRIORITY JOURNAL; PROMOTER REGION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSCRIPTION INITIATION SITE; ACETYLATION; CELL CULTURE; CHROMATIN ASSEMBLY AND DISASSEMBLY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; LYMPHOCYTE ACTIVATION; METABOLISM; PHYSIOLOGY;

ACETYLATION; CELLS, CULTURED; CHROMATIN; CHROMATIN ASSEMBLY AND DISASSEMBLY; CRYOPRESERVATION; CYTOKINES; GENE EXPRESSION REGULATION; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INTERFERON-GAMMA; LYMPHOCYTE ACTIVATION; MESENCHYMAL STROMAL CELLS; PROMOTER REGIONS, GENETIC; RNA, MESSENGER; TRANSCRIPTION INITIATION SITE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84990857069     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1016/j.jcyt.2016.05.017     Document Type: Article

References (56)

1. [1] Friedenstein, A.J., Chailakhjan, R.K., Lalykina, K.S., The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells. Cell Tissue Kinet 3 (1970), 393–403.
2. [2] Friedenstein, A.J., Chailakhyan, R.K., Latsinik, N.V., Panasyuk, A.F., Keiliss-Borok, I.V., Stromal cells responsible for transferring the microenvironment of the hemopoietic tissues. Cloning in vitro and retransplantation in vivo. Transplantation 17 (1974), 331–340.
3. [3] Dominici, M., Le, B.K., Mueller, I., Slaper-Cortenbach, I., Marini, F., Krause, D., et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8 (2006), 315–317.
4. [4] Pittenger, M.F., Mackay, A.M., Beck, S.C., Jaiswal, R.K., Douglas, R., Mosca, J.D., et al. Multilineage potential of adult human mesenchymal stem cells. Science 284 (1999), 143–147.
5. [5] Bernardo, M.E., Fibbe, W.E., Mesenchymal stromal cells: sensors and switchers of inflammation. Cell Stem Cell 13 (2013), 392–402.
6. [6] English, K., Mechanisms of mesenchymal stromal cell immunomodulation. Immunol Cell Biol 91 (2013), 19–26.
7. [7] Le, B.K., Davies, L.C., Mesenchymal stromal cells and the innate immune response. Immunol Lett, 10, 2015.
8. [8] Ren, G., Zhang, L., Zhao, X., Xu, G., Zhang, Y., Roberts, A.I., et al. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2 (2008), 141–150.
9. [9] Krampera, M., Mesenchymal stromal cell ‘licensing’: a multistep process. Leukemia 25 (2011), 1408–1414.
10. [10] Benvenuto, F., Ferrari, S., Gerdoni, E., Gualandi, F., Frassoni, F., Pistoia, V., et al. Human mesenchymal stem cells promote survival of T cells in a quiescent state. Stem Cells 25 (2007), 1753–1760.
11. [11] Stagg, J., Pommey, S., Eliopoulos, N., Galipeau, J., Interferon-gamma-stimulated marrow stromal cells: a new type of nonhematopoietic antigen-presenting cell. Blood 107 (2006), 2570–2577.
12. [12] English, K., Barry, F.P., Field-Corbett, C.P., Mahon, B.P., IFN-gamma and TNF-alpha differentially regulate immunomodulation by murine mesenchymal stem cells. Immunol Lett 110 (2007), 91–100.
13. [13] Krampera, M., Cosmi, L., Angeli, R., Pasini, A., Liotta, F., Andreini, A., et al. Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells 24 (2006), 386–398.
14. [14] Plumas, J., Chaperot, L., Richard, M.J., Molens, J.P., Bensa, J.C., Favrot, M.C., Mesenchymal stem cells induce apoptosis of activated T cells. Leukemia 19 (2005), 1597–1604.
15. [15] Ryan, J.M., Barry, F., Murphy, J.M., Mahon, B.P., Interferon-gamma does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells. Clin Exp Immunol 149 (2007), 353–363.
16. [16] Sheng, H., Wang, Y., Jin, Y., Zhang, Q., Zhang, Y., Wang, L., et al. A critical role of IFNgamma in priming MSC-mediated suppression of T cell proliferation through up-regulation of B7-H1. Cell Res 18 (2008), 846–857.
17. [17] Francois, M., Romieu-Mourez, R., Li, M., Galipeau, J., Human MSC suppression correlates with cytokine induction of indoleamine 2,3-dioxygenase and bystander M2 macrophage differentiation. Mol Ther 20 (2012), 187–195.
18. [18] Meisel, R., Zibert, A., Laryea, M., Gobel, U., Daubener, W., Dilloo, D., Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood 103 (2004), 4619–4621.
19. [19] Mellor, A.L., Munn, D.H., Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation?. Immunol Today 20 (1999), 469–473.
20. [20] Krampera, M., Galipeau, J., Shi, Y., Tarte, K., Sensebe, L., Immunological characterization of multipotent mesenchymal stromal cells–The International Society for Cellular Therapy (ISCT) working proposal. Cytotherapy 15 (2013), 1054–1061.
21. [21] Francois, M., Copland, I.B., Yuan, S., Romieu-Mourez, R., Waller, E.K., Galipeau, J., Cryopreserved mesenchymal stromal cells display impaired immunosuppressive properties as a result of heat-shock response and impaired interferon-gamma licensing. Cytotherapy 14 (2012), 147–152.
22. [22] Menard, C., Pacelli, L., Bassi, G., Dulong, J., Bifari, F., Bezier, I., et al. Clinical-grade mesenchymal stromal cells produced under various good manufacturing practice processes differ in their immunomodulatory properties: standardization of immune quality controls. Stem Cells Dev 22 (2013), 1789–1801.
23. [23] Moll, G., Alm, J.J., Davies, L.C., von Bahr, L., Heldring, N., Stenbeck-Funke, L., et al. Do cryopreserved mesenchymal stromal cells display impaired immunomodulatory and therapeutic properties?. Stem Cells 32 (2014), 2430–2442.
24. [24] Pollock, K., Sumstad, D., Kadidlo, D., McKenna, D.H., Hubel, A., Clinical mesenchymal stromal cell products undergo functional changes in response to freezing. Cytotherapy 17 (2015), 38–45.
25. [25] Phinney, D.G., Biochemical heterogeneity of mesenchymal stem cell populations: clues to their therapeutic efficacy. Cell Cycle 6 (2007), 2884–2889.
26. [26] Luetzkendorf, J., Nerger, K., Hering, J., Moegel, A., Hoffmann, K., Hoefers, C., et al. Cryopreservation does not alter main characteristics of Good Manufacturing Process-grade human multipotent mesenchymal stromal cells including immunomodulating potential and lack of malignant transformation. Cytotherapy 17 (2015), 186–198.
27. [27] Ren, G., Su, J., Zhang, L., Zhao, X., Ling, W., L'huillie, A., et al. Species variation in the mechanisms of mesenchymal stem cell-mediated immunosuppression. Stem Cells 27 (2009), 1954–1962.
28. [28] Robinson, C.M., Hale, P.T., Carlin, J.M., The role of IFN-gamma and TNF-alpha-responsive regulatory elements in the synergistic induction of indoleamine dioxygenase. J Interferon Cytokine Res 25 (2005), 20–30.
29. [29] Rada-Iglesias, A., Wysocka, J., Epigenomics of human embryonic stem cells and induced pluripotent stem cells: insights into pluripotency and implications for disease. Genome Med, 3, 2011, 36.
30. [30] Bernstein, B.E., Kamal, M., Lindblad-Toh, K., Bekiranov, S., Bailey, D.K., Huebert, D.J., et al. Genomic maps and comparative analysis of histone modifications in human and mouse. Cell 120 (2005), 169–181.
31. [31] Ernst, J., Kheradpour, P., Mikkelsen, T.S., Shoresh, N., Ward, L.D., Epstein, C.B., et al. Mapping and analysis of chromatin state dynamics in nine human cell types. Nature 473 (2011), 43–49.
32. [32] Guenther, M.G., Levine, S.S., Boyer, L.A., Jaenisch, R., Young, R.A., A chromatin landmark and transcription initiation at most promoters in human cells. Cell 130 (2007), 77–88.
33. [33] Nielsen, S.J., Schneider, R., Bauer, U.M., Bannister, A.J., Morrison, A., O'Carroll, D., et al. Rb targets histone H3 methylation and HP1 to promoters. Nature 412 (2001), 561–565.
34. [34] Allan, R.S., Zueva, E., Cammas, F., Schreiber, H.A., Masson, V., Belz, G.T., et al. An epigenetic silencing pathway controlling T helper 2 cell lineage commitment. Nature 487 (2012), 249–253.
35. [35] Cuerquis, J., Romieu-Mourez, R., Francois, M., Routy, J.P., Young, Y.K., Zhao, J., et al. Human mesenchymal stromal cells transiently increase cytokine production by activated T cells before suppressing T-cell proliferation: effect of interferon-gamma and tumor necrosis factor-alpha stimulation. Cytotherapy 16 (2014), 191–202.
36. [36] Lo Surdo, J.L., Millis, B.A., Bauer, S.R., Automated microscopy as a quantitative method to measure differences in adipogenic differentiation in preparations of human mesenchymal stromal cells. Cytotherapy 15 (2013), 1527–1540.
37. [37] Lo Surdo, J., Bauer, S.R., Quantitative approaches to detect donor and passage differences in adipogenic potential and clonogenicity in human bone marrow-derived mesenchymal stem cells. Tissue Eng Part C Methods 18 (2012), 877–889.
38. [38] Lynch, P.J., Thompson, E.E., McGinnis, K., Rovira Gonzalez, Y.I., Lo Surdo, J., Bauer, S.R., et al. Chromatin changes at the PPAR-gamma2 promoter during bone marrow-derived multipotent stromal cell culture correlate with loss of gene activation potential. Stem Cells 33 (2015), 2169–2181.
39. [39] Hellemans, J., Mortier, G., De, P.A., Speleman, F., Vandesompele, J., qBase relative quantification framework and software for management and automated analysis of real-time quantitative PCR data. Genome Biol, 8, 2007, R19.
40. [40] Hellemans, J., Vandesompele, J., Selection of reliable reference genes for RT-qPCR analysis. Methods Mol Biol 1160 (2014), 19–26, 10.1007/978-1-4939-0733-5_3.:19-26.
41. [41] Vandesompele, J., De, P.K., Pattyn, F., Poppe, B., Van, R.N., De, P.A., et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol, 3, 2002 RESEARCH0034.
42. [42] Benjamini, Y., Hochberg, Y., Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Stat Soc B Met 57 (1995), 289–300.
43. [43] Lee, R.H., Pulin, A.A., Seo, M.J., Kota, D.J., Ylostalo, J., Larson, B.L., et al. Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell 5 (2009), 54–63.
44. [44] Stultz, B.G., McGinnis, K., Thompson, E.E., Lo Surdo, J.L., Bauer, S.R., Hursh, D.A., Chromosomal stability of mesenchymal stromal cells during in vitro culture. Cytotherapy 18 (2016), 336–343.
45. [45] Bellayr, I.H., Catalano, J.G., Lababidi, S., Yang, A.X., Lo Surdo, J.L., Bauer, S.R., et al. Gene markers of cellular aging in human multipotent stromal cells in culture. Stem Cell Res Ther, 5, 2014, 59.
46. [46] Mindaye, S.T., Ra, M., Lo Surdo, J.L., Bauer, S.R., Alterman, M.A., Global proteomic signature of undifferentiated human bone marrow stromal cells: evidence for donor-to-donor proteome heterogeneity. Stem Cell Res 11 (2013), 793–805.
47. [47] Mindaye, S.T., Ra, M., Lo Surdo, J.L., Bauer, S.R., Alterman, M.A., Improved proteomic profiling of the cell surface of culture-expanded human bone marrow multipotent stromal cells. J Proteomics 78 (2013), 1–14.
48. [48] Galipeau, J., The mesenchymal stromal cells dilemma—does a negative phase III trial of random donor mesenchymal stromal cells in steroid-resistant graft-versus-host disease represent a death knell or a bump in the road?. Cytotherapy 15 (2013), 2–8.
49. [49] Ikebe, C., Suzuki, K., Mesenchymal stem cells for regenerative therapy: optimization of cell preparation protocols. Biomed Res Int, 2014, 2014, 951512.
50. [50] Bustin, S.A., Benes, V., Garson, J.A., Hellemans, J., Huggett, J., Kubista, M., et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem 55 (2009), 611–622.
51. [51] Bustin, S.A., Beaulieu, J.F., Huggett, J., Jaggi, R., Kibenge, F.S., Olsvik, P.A., et al. MIQE precis: practical implementation of minimum standard guidelines for fluorescence-based quantitative real-time PCR experiments. BMC Mol Biol, 11, 2010, 74, 10.1186/1471-2199-11-74.:74-11.
52. [52] Christova, R., Jones, T., Wu, P.J., Bolzer, A., Costa-Pereira, A.P., Watling, D., et al. P-STAT1 mediates higher-order chromatin remodelling of the human MHC in response to IFNgamma. J Cell Sci 120 (2007), 3262–3270.
53. [53] Ni, Z., Karaskov, E., Yu, T., Callaghan, S.M., Der, S., Park, D.S., et al. Apical role for BRG1 in cytokine-induced promoter assembly. Proc Natl Acad Sci USA 102 (2005), 14611–14616.
54. [54] Buro, L.J., Chipumuro, E., Henriksen, M.A., Menin and RNF20 recruitment is associated with dynamic histone modifications that regulate signal transducer and activator of transcription 1 (STAT1)-activated transcription of the interferon regulatory factor 1 gene (IRF1). Epigenetics Chromatin, 3, 2010, 16.
55. [55] Satoh, J., Tabunoki, H., A comprehensive profile of ChIP-Seq-Based STAT1 target genes suggests the complexity of STAT1-Mediated gene regulatory mechanisms. Gene Regul Syst Bio 7 (2013), 41–56.
56. [56] Roddy, G.W., Oh, J.Y., Lee, R.H., Bartosh, T.J., Ylostalo, J., Coble, K., et al. Action at a distance: systemically administered adult stem/progenitor cells (MSCs) reduce inflammatory damage to the cornea without engraftment and primarily by secretion of TNF-alpha stimulated gene/protein 6. Stem Cells 29 (2011), 1572–1579.